Trial result ·
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This trial tested amivantamab given alone in people with colorectal cancer. Their cancer had spread and no longer responded to chemotherapy. They had tried 2-3 earlier lines of treatment. Their tumors had no changes in the RAS and BRAF genes. A key outer part of EGFR was also unchanged. Tumors with extra copies of HER2 were left out. People were put into groups by tumor side and past anti-EGFR drugs. Each person got the drug into a vein every 2 weeks. In all, 94 people took part in this open-label trial.
What they found
People were followed for a median of 11.9 months. In the left-side group with no past anti-EGFR drug, tumors shrank in 5 of 17. In the left-side group with past anti-EGFR drugs, it was 10 of 54. In the right-side group, tumors shrank in 10 of 23. Across groups, shrinkage lasted a median of 6.1 to 9.8 months. Median time before the cancer grew ran from 3.7 to 5.7 months. The most common severe side effects were rash, skin acne and low blood albumin. One person stopped the drug due to a side effect.
What it means for patients
The authors say the drug showed lasting effects against this cancer. They say this held true whatever the tumor side. It also held true with or without past anti-EGFR drugs. They say its safety looked like what is seen in lung cancer. Late-stage trials now test the drug along with chemotherapy.
Why it is not certain yet
This was an early trial with no comparison group. The groups held only 17, 54 and 23 people. People and doctors knew which drug was given. The abstract does not say how long people lived overall. Only people with certain tumor gene results could join.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
PubMed · PMID 42013403We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Colorectal cancer publications